LJ-2698 is an adenosine A3 receptor antagonist under investigation for treating emphysema and DKD (Diabetic Kidney Disease). In mouse lung models, LJ-2698 effectively mitigates elastase-induced adverse effects and inhibits matrix metalloproteinase activity and apoptosis. Additionally, it is being explored for its potential in treating diabetic nephropathy, successfully preventing various types of kidney damage in mice.
Molekulargewicht:
412.29
CAS Nummer:
[945457-84-1]
Formel:
C16H15Cl2N5O2S
T202459
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten